Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tofacitinib + triamcinolone
- Development stage
- Unknown
- Lead developer
- AIIMS Bhubaneswar
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Topical
01
Overview
Tofacitinib + triamcinolone is a combination therapy being evaluated in a Phase 4 clinical trial by the All India Institute of Medical Sciences (AIIMS), Bhubaneswar, for the treatment of moderate to severe oral lichen planus (OLP). The regimen consists of oral tofacitinib, a small molecule Janus kinase (JAK) inhibitor that selectively targets JAK1 and JAK3 to interrupt the JAK-STAT signaling pathway, and topical triamcinolone, a potent corticosteroid that acts as a glucocorticoid receptor agonist. This dual approach aims to provide superior anti-inflammatory and immunomodulatory effects compared to standard topical steroid monotherapy, particularly in patients with erosive OLP who are resistant to conventional treatments or experience frequent relapses.
- Other names
- tofacitinib and triamcinoloneadd-on tofacitinib with triamcinolone
02
Targets
JAK3 (Janus kinase 3)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)GR (Glucocorticoid receptor)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on tofacitinib + triamcinolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tofacitinib + triamcinolone.